SCHEMBL4483534

SCHEMBL4483534

CC(C)NC(=O)NSc1ccc2[nH]c(-c3ccccc3-c3nc4cc(NC(=S)NC(C)C)ccc4[nH]3)nc2c1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
MAPT P10636 4/20 0.42
KDM4E B2RXH2 6/20 0.42
TP53 P04637 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
RAB9A P51151 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
NPC1 O15118 2/20 0.38
HTT P42858 1/20 0.37
MAPK1 P28482 2/20 0.36
HPSE Q9Y251 1/20 0.35
LDLR P01130 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
QPCT Q16769 1/20 0.35
ADORA2A P29274 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4483537 0.86 KDM4E (0.54) ALDH1A1MAPTKDM4ETP53RXFP1
SCHEMBL4496023 0.84 KDM4E (0.51) ALDH1A1MAPTKDM4ETP53RXFP1
SCHEMBL4508663 0.83 KDM4E (0.44) ALDH1A1MAPTKDM4ETP53RXFP1
SCHEMBL4496122 0.72 KDM4E (0.61) ALDH1A1MAPTKDM4ETP53RAB9A
SCHEMBL4496201 0.72 TP53 (0.49) ALDH1A1MAPTKDM4ETP53RXFP1
SCHEMBL4496027 0.72 KDM4E (0.65) ALDH1A1MAPTKDM4ETP53RXFP1
SCHEMBL4508668 0.70 MAPT (0.50) ALDH1A1MAPTKDM4ETP53RXFP1
SCHEMBL4496830 0.67 PTPRC (0.53) ALDH1A1MAPTKDM4ETP53RXFP1
SCHEMBL4483540 0.67 TP53 (0.40) ALDH1A1MAPTKDM4ETP53RXFP1
SCHEMBL4480173 0.67 DGAT1 (0.60) ALDH1A1MAPTKDM4ETP53RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482373-B2 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2009-01-27 US disclosed
US-20070027200-A1 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2007-02-01 US disclosed
US-7132439-B2 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2006-11-07 US disclosed
US-20040029925-A1 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2004-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027200-A1 Bis-benzimidazoles and related compounds as potassium channel modulators KCNJ2, KCNA3, KCNB2 ALDH1A1 2373/4885MAPT 2367/4885KDM4E 488/4885
US-20040029925-A1 Bis-benzimidazoles and related compounds as potassium channel modulators KCNJ2, KCNA3, KCNB2 ALDH1A1 2373/4885MAPT 2367/4885KDM4E 488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.